升血小板胶囊联合重组人血小板生成素治疗特发性血小板减少性紫癜的疗效观察

目的观察升血小板胶囊联合重组人血小板生成素注射液治疗特发性血小板减少性紫癜(ITP)的临床疗效。方法选取2016年1月—2016年10月在信阳市中心医院住院治疗的ITP患者68例,随机分为对照组和治疗组,每组各34例。对照组皮下注射重组人血小板生成素注射液,300 U/(kg·d),1次/d。治疗组在对照组的基础上口服升血小板胶囊,1.8 g/次,3次/d。两组患者均治疗14 d。评价两组患者临床疗效,同时比较治疗前后两组患者血小板计数和血清相关血小板抗体(PAlgG)升高例数差异。结果治疗后,对照组临床总有效率为70.59%,显著低于治疗组的91.18%,两组比较差异具有统计学意义(P0.05)。治疗后,两组血小板计数均明显升高,同组比较差异具有统计学意义(P0.05);且治疗组患者血小板计数水平显著高于对照组,两组比较差异具有统计学意义(P0.05)。治疗后,治疗组血清PAIgG水平大于108 ng/10PA的例数显著少于对照组,两组比较差异具有统计学意义(P0.05)。结论血小板胶囊联合重组人血小板生成素能显著缩短ITP患者血小板恢复的时间,提高临床效果,具有一定的临床推广应用价值。

Clinical observation of Shengxuexiaoban Capsules combined with Recombinant Human Thrombopoietin Injection in treatment of idiopathic thrombocytopenic purpura

Objective To observe the effect of Shengxuexiaoban Capsules combined with Recombinant Human Thrombopoietin Injection in treatment of idiopathic thrombocytopenic purpura (ICP). Methods Patients (68 cases) with ICP in Xinyang Central Hospital from January 2016 to October 2016 were randomly divided into control and treatment groups, and each group had 34 cases. Patients in the control group were subcutaneous injection administered with Recombinant Human Thrombopoietin Injection, 300 U/(kg·d), once daily. Patients in the treatment group were po administered with Shengxuexiaoban Capsules on the basis of the control group, 1.8 g/time, three times daily. Patients in two groups were treated for 14 d. After treatment, clinical efficacy was evaluated, and the difference of the platelet counts and the serum PalgG level in two groups before and after treatment was compared. Results After treatment, the clinical efficacy in the control group was 70.59%, which was significantly lower than 91.18% in the treatment group, and there were differences between two groups (P<0.05). After treatment, the platelet counts in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the platelet counts in the treatment group were significantly higher than that in the control group, with significant difference between two groups (P<0.05). After treatment, the patients whose serum PalgG level more than 108 ng/10PA in the treatment group were significantly less than patients in the control group, with significant difference between two groups (P<0.05). Conclusion Shengxuexiaoban Capsules combined with Recombinant Human Thrombopoietin Injection can significantly shorten the recovery time of platelet in treatment of idiopathic thrombocytopenic purpura, and improve the clinical effect, which has a certain clinical application value.